Dr. Gaetano Morelli Named Chief Medical Officer at Altasciences
Altasciences announced today the appointment of Dr. Gaetano Morelli as Chief Medical Officer, effective May 14, 2020.
Altasciences Completes Phase I Study on Gimsilumab for ARDS in COVID-19
Altasciences has completed a Phase I study for the development of gimsilumab, a fully human monoclonal antibody that targets granulocyte-macrophage colony stimulating factor (GM-CSF), found to be up-regulated in SARS CoV-2 in patients with or at risk of developing acute respiratory distress syndrome (ARDS).
Altasciences and Amador Bioscience Announce Strategic Collaboration
Altasciences, a CRO in the U.S. and Canada specializing in a flexible, innovative approach to comprehensive early stage drug development, announced today that they have entered into an agreement with Amador Bioscience.
Altasciences Adds Comprehensive Contract Manufacturing and Analytical Services to its Early Phase Research Offering
Altasciences, a mid-size CRO specializing in a flexible, innovative approach to providing comprehensive early stage drug development from lead candidate selection to proof of concept, today announced that it has acquired Alliance Contract Pharma. This acquisition adds small molecule contract manufacturing and analytical services from API to commercialization, including commercial manufacturing, GMP warehouse storage, and clinical supply distribution, to Altasciences’ full-service preclinical, clinical, and bioanalytical offerings.
Paul Sidney Joins Altasciences as Senior Director, Compliance and Regulatory Affairs
Altasciences announced the addition of Paul Sidney to their Compliance and Regulatory Affairs team as Senior Director.